Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.
Small Pharma’s Chief Medical and Scientific Officer, Carol Routledge, on DMT’s power to treat Major Depressive Disorder; atai creates subsidiary to target depression with precision psychiatry; How COVID-19 opened the door to a new era in psychedelic medicine.
The Psychedelics as Medicine Report: Third Edition; Seattle City Council passes resolution to decriminalise psychedelics; 24 hour countdown to PSYCH Investor Summit: Data & Technology
NeonMind’s President and CEO, Robert Tessarolo, on psilocybin’s efficacy in treating obesity; MDMA, LSD and magic mushrooms: are these drugs the future of therapy? CaaMTech raises US$22m in Series A funding round
NeonMind’s President and CEO, Robert Tessarolo, on psilocybin’s efficacy in treating obesity; MDMA, LSD and magic mushrooms: are these drugs the future of therapy? CaaMTech raises US$22m in Series A funding round
NeonMind’s President and CEO, Robert Tessarolo, on psilocybin’s efficacy in treating obesity; MDMA, LSD and magic mushrooms: are these drugs the future of therapy? CaaMTech raises US$22m in Series A funding round
Tryp Therapeutics’ CEO Greg McKee on the next wave of psychedelic medicines; The worldview-changing drugs poised to go mainstream;
The DEA bolsters bolsters support for psychedelic research
RYAH Group's CEO Gregory Wagner on drug delivery through IoT
Awakn Life Sciences to conduct ketamine trials for gambling addiction
California bill to legalise psychedelics shelved until 2022
Psychedelic-assisted therapy enhanced through VR technology; California bill to legalise psychedelics clears another hurdle; Biomind Labs' Phase II clinical trial approved by Brazilian regulator
Beckley Psytech’s CEO Cosmo Feilding Mellen on raising US$80 million; Awakn Life Sciences begins trading on OTCQB; atai Life Sciences creates subsidiary for salvia divinorum derivatives. Read more in Issue 42 of the Psychedelics Newsletter.
Overwhelming majority of Canadians support legalisation of psilocybin; Could psychedelic drugs revolutionise mental healthcare in the UK? Cybin becomes first psychedelic company to list on the New York Stock Exchange. Read more in Issue 41 of the Psychedelics Newsletter
BHMNC Brain Health on precision psychiatry and psychedelics;
Global psychedelics research institute launched in Melbourne with AU$40m in funding; Poll reveals majority of Canadians support legalisation of psilocybin-assisted therapy. Read more in Issue 40 of the Psychedelics Newsletter
Field Trip’s Co-founder and Executive Chairman Ronan Levy on investor opportunities following Nasdaq listing; Cybin to list on NYSE’s Small Cap Market to finance expansion; The Times: Psychedelic firms take a trip over the Atlantic in search of funds. Read more in Issue 39 of the Psychedelics Newsletter.
Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.
Subscribe to the Psychedelics Newsletter
Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.
